Company intelligence / Profile preview
StemRIM
Ibaraki-shi or Osaka-shi* (*sources mention both), Osaka Prefecture/Ibaraki City area* (*based on HQ location), Japanstemrim.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
StemRIM has developed a novel regenerative medicine platform that uses proprietary compounds to activate endogenous stem cells, promoting functional regeneration of damaged tissues. Its lead candidate, PJ1/HMGB1 peptide, has advanced to Phase II clinical trials in several indications including epidermolysis bullosa and cerebral infarction. Preclinical programs target additional diseases involving tissue injury. The approach offers an alternative to traditional cell therapies by avoiding the need for ex vivo manipulation or transplantation of living cells[1][4].
- Therapeutic areas
- ImmunologyDermatologyRheumatologyGastroenterologyCardiovascularNeurology
- Modalities
- Regeneration-inducing small molecules/peptides (e.g., HMGB1 peptides)Gene therapy (preclinical)Autologous cell sampling device
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaboration with Osaka University since foundation; no major pharma partnerships listed but strong academic collaboration[1][2]
Beyond the preview
Go deeper on StemRIM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemRIM.